A true mentor and pioneer in medical genetics by Hayden, Michael
S7       June 2016, Vol. 106, No. 6 (Suppl 1)
LEGACY
I still remember very vividly the first lecture that I ever heard from Prof. 
Peter Beighton. This was shortly after he arrived in Cape Town in 1972. 
Were it not for Peter, I do not think that I would ever have entered the 
field of human genetics. With his enthusiasm and brilliant presentation, 
and the capability of evoking excitement and dreams, Peter Beighton 
inspired me. Shortly after I had heard that lecture, I presented myself at 
the Department of Human Genetics, which was newly established and 
the first in Africa. I asked him whether I could participate in any research 
projects. I was particularly drawn to his research projects, as it appeared 
that they opened up new possibilities for understanding biology in 
different populations, which might have relevance for the general 
population. Peter’s stories of his hiking through the Sahara Desert with 
the Tuareg, and his stories from different populations in Africa, inspired 
me and elucidated for me for the first time the power of studying rare 
families and their ability to inform general rules of biology.
As a medical student, I then pursued many research projects with 
Prof. Beighton. I recall travelling with him to the Kalahari Desert in an 
effort to understand and explore the basis of steatopygia in the Khoisan 
people. I also recall very vividly the first introduction that Peter made 
for me to patients with increased bone density. Peter was an expert 
and had already specialised in patients with bone dysplasias, including 
increased bone density, and had authored authoritative manuscripts 
on sclerosing bone dyplasias.[1,2] I was fortunate to go with Peter to 
visit families with sclerosteosis in different parts of the country. These 
were very moving moments as I saw, first hand, the impact of this 
increased bone density on patients.[3,4] In a few instances, we actually 
saw, to our deep sadness, the increased intracranial pressure leading 
to severe symptoms and occasionally also to death, as a result of the 
increased density of the skull. These vivid images have stayed with me 
throughout my life and have also inspired me to look and see what we 
could learn from and do for those with rare conditions.
After I moved to Vancouver, to the University of British Columbia 
from Harvard Medical School in 1983, and founded my first company, 
Xenon Genetics, I remembered those patients with sclerosteosis and 
went back to Peter. I persuaded him and others to send a postdoctoral 
fellow to the USA in an effort to bring DNA to clone that particular gene. 
When I looked at the X-rays of these patients with Peter, it was obvious 
that this was not a disorder of osteoclast overactivity, but appeared to 
be most likely due to unregulated overexpression of the osteoblast. I 
already recognised at that point that an understanding of the cause for 
sclerosteosis could potentially lead to a fundamental understanding 
of the regulation of osteoblast activity. This, in turn, could lead to the 
opportunity to influence osteoblast activity, with the potential to treat 
osteoporosis in the general population. With this particular perspective, 
the gene for sclerosteosis was cloned and discovered.[5] The protein 
was termed ‘sclerostin’, and this represented the discovery of the key 
regulator of transcriptional activity of osteoblasts in humans. Knocking 
this out or deleting it, as was seen with patients with sclerosteosis, 
resulted in osteoblast hyperactivity and increased bone density. As a 
result of this, is it was apparent that if one developed an antagonist to 
this transcriptional regulator, replicating what is seen in sclerosteosis, 
this would lead to upregulation of the osteoblast. This eventually led 
to the development of humanised monoclonal antibodies that inhibit 
this particular transcriptional regulator, resulting in upregulation of the 
osteoblast. Humanised monoclonal antibodies against this novel target 
are currently in phase III development (Amgen, USA), and offer hope for 
the development of new approaches for treatment of osteoporosis in the 
general population. This has also opened up a field of investigation into 
regulation of osteoblast function.
The particular concept that by studying a rare disorder, one could 
derive insights that are pertinent to the general population and general 
biology, and would lend therapeutic targets, was a very landmark 
inspiring moment for me. It continues to be a beacon to me in my 
approach to human genetics and the approaches to drug development 
for the future. Genetically validated targets still represent a most 
important approach to ensure success in drug development. This was 
also exemplified by our search for genes causing congenital insensitivity 
to pain. I was first aware of this condition on seeing a few kindreds of the 
Cape Malay community practise a unique ritual, where individuals could 
pierce their own body parts, including the tongue, or walk on nails, and 
experience no pain. I was immediately struck that if there was a way to 
repeat that phenomenon with a drug, this could lead to new approaches 
to treating pain. This led to the search for the gene underlying congenital 
insensitivity to pain, which identified Nav1.7 as a target and has led to 
novel approaches to drug development for pain.[6]
When I finished my medical studies, I continued in an internal 
medicine residency at Groote Schuur Hospital (GSH). At the same 
time, I approached Prof. Beighton again with a view to doing a PhD 
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in medical genetics. At one of the first clinics I went to in early 1977, 
patients attended with inherited chorea, which was not deemed to be 
Huntington’s disease (HD) as it was believed that HD did not exist in 
South Africa (SA). I saw the impact of this disease on families as we made 
home visits, and continued to identify patients with inherited chorea or 
HD in the population. As a result of this, when I told Prof. Beighton 
that I wanted to study HD, his approach was ‘seems very reasonable, H 
is for Hayden and H is for Huntington’s chorea; seems like a good plan’. 
Peter’s approach to mentorship was profound and inspiring. His intense 
enthusiastic engagement with the day-to-day activities of the scientific 
project was exciting. He maintained passionate involvement in all that 
happened and was also committed to communicating our findings to 
the population and to the scientific community as quickly as possible. 
This infectious enthusiasm, as well as his ability to give me the freedom 
to pursue this disease, not only in the Western Cape but also throughout 
every mental hospital in SA, was really an opportunity for me to express 
my own sense of wonder, curiosity and hope for new understanding of 
this devastating disease. This study itself ended up changing the view of 
the epidemiology of HD in Africa.[7-10]
Peter also supported my approach to the development of the first 
multiracial HD clinic in GSH in 1978. Together with Jim McGregor, the 
Chief of Neurology, a non-racial clinic (one of the first) was established, 
which was led by medical genetics but incorporated neurology, 
psychiatry, social work and other modalities to provide comprehensive 
care to patients. Peter recognised early on that the key to providing 
support for patients was also to take care of the caregivers and the 
family.[11] The approach to caring was very significant as we recognised 
that the patient is not the only focus for care, but also the family and 
the patient’s place within their own community. Peter also encouraged 
me to believe that the importance of this project was profound and 
central to the development of human genetics in SA. He supported 
the investigation of HD in Mauritius[12] and other small communities 
within southern Africa.[10,13] He also helped to raise funding from 
different sources, such as the Mauerberger Foundation, in an effort to 
allow this project to reach its particular goals. In a sense, this was all 
serendipity. Serendipity that, firstly, I was able to have this opportunity 
to work with Prof. Beighton, but also serendipity that I saw patients 
with HD at the first clinic that I went to, which then supported my 
inquiry and my pursuit of knowledge that continues to this day.
A good test of mentorship is the ability to inspire others, a sense of 
play and also the recognition that together we can change the landscape 
and bring new knowledge to the world. Peter made me think that we 
could change the world, even from Cape Town, and that a sense of 
adventure and play was a very important component and a lifelong 
gift that empowered us to express our fullest potential. Another 
example of his profound leadership was his unique approach to giving 
lectures. His lectures were always stimulating, exciting, inspiring and 
sometimes shocking. He quickly educated all of his trainees on how 
to give a lecture, how to focus, how to draw attention, how to bring 
humour, how to shock and also how to inspire. Peter gave advice as to 
how to tell a story and develop a narrative; this particular skill was very 
important for an early fledgling scientist. Peter’s inspiration in this way 
has played a key role in my ability to improve my communication skills 
throughout my life. Peter always shared his slides, his books and his 
perspectives with me in the most generous way, and was always willing 
to provide critique and support, at all times of the day, nights, weekends 
and holidays. He taught me simple principles, such as how to create a 
captivating title in a talk, how to have figures that tell a story, and how 
to make sure that the presentation is not filled with too much data that 
would be best put within a manuscript. How to arrange your slides 
with the recognition that a picture is better than a thousand words is a 
principle that is still deeply embedded in me to this day.
Another exciting part of being in the Department of Human Genetics 
in the ‘70s was Peter welcoming all of his trainees to interact with 
visiting professors who came from all over the world. I still recall 
with great fondness the visits of David Smith, Alan Emery, Jurgen 
Spranger and others to SA in the late ‘70s. I remember showing 
David Smith a patient with a smooth philtrum and a particular facies 
with some epicanthic folds and obvious developmental delay. This 
resulted in the first child in SA being identified with fetal alcohol 
syndrome. This presentation was later submitted and published in 
the SAMJ. [14] As part of this visit, I also identified, with David Smith, 
the first patient with fetal hydantoin syndrome, which was quickly 
translated to publication in the SAMJ. [15] The friendships that were 
encouraged by Peter’s generosity of spirit had influence throughout 
my life. I visited David Smith and Arno Motluskly in Seattle and also 
Judith Hall, who continued to play a very important role in my career. 
Judith was the person who persuaded me to come to the University of 
British Columbia when I was doing a fellowship at Boston Children’s 
Hospital. 
Even though Peter was thrilled with and had a keen sense of 
enjoyment of his trainees and people around him, he also understood 
that for each of us to make a mark, it was most important for us to 
travel and to undergo additional training in different parts of the 
world. I had long discussions with Peter about where to go and he 
provided sage advice about different parts of the USA and Canada, 
to which I applied. I eventually chose to go to Boston Children’s 
Hospital, with his complete blessing and support. A key feature of 
those years in training under the guidance and mentorship of Peter 
Beighton was the strong sense that my trusted advisor really believed 
in me, my abilities and the objectives of my study. This empowerment 
brought not only intellectual courage but also technical courage, 
as Peter also inspired us all to collaborate with others at UCT and 
elsewhere. These collaborations led to the first investigation of 
neuroendocrine abnormalities, including impaired prolactin release, 
in HD, published with Arthur Vinik and others in the Department of 
Medicine in 1977 in The Lancet.[16]
Peter’s mentorship of my development at this important stage has 
allowed me to incorporate principles that have certainly improved my 
ability to be a mentor. I have now mentored well over 150 people, and, 
for me, the independent success of these trainees is a very important 
part of the sense of meaning and accomplishment that I carry with me 
at this different stage of my career. The process of understanding this, 
and recognising that the success of your trainees is the greatest source 
of professional satisfaction, really goes back to Peter and his ability to 
be a role model in this way. Another important attribute that Peter 
has was that even when the day looked bleak and the opportunities 
for funding looked grim, the sense of irrational optimism and a 
positive perspective was ever present. This, coupled with a sense of 
adventure, a sense of humour and the recognition of what one learns 
by observing nature around you, were key ingredients in our training.
The opportunity to accompany Peter on numerous trips throughout 
the Western Cape, the Transvaal, the Kalahari Desert and, for some, 
even to Tristan da Cunha, provided sources of great inspiration, 
and demonstration that by observing nature around you and rare 
populations, there was an opportunity to learn profoundly and gain 
deep insight that can have relevance for human biology as a whole. These 
principles are well recognised today, but we had already fully accepted 
them in the mid-70s in the Department of Human Genetics in SA. This 
sense of work feeling like play, and the feeling that we did not work for a 
living but rather with a sense of fun and excitement in everything we did, 
was a key reward in that department. It was a great, wonderful adventure.
I am deeply grateful to Peter for his mentorship, and for the more 
than 40 years of friendship, fellowship and mutual support that has 
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occurred over this particular period. I wish Peter the best of health and 
the best of success, and also want to give a deep acknowledgement not 
only to Peter but to Greta, his partner for life, who provided undying 
support for everything we did with a sense of warmth, encouragement, 
generosity of spirit and also a sense of great fun and adventure.
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